Used alone, each medication stops or slows hair loss. Together, the response rate approaches 94% — because they work through entirely different mechanisms that complement each other.
By Dr. Teja V. Surapaneni, MD, MS • Board-Certified Internal Medicine • May 2026
Used alone, finasteride stops hair loss in about 86% of men and regrows hair in about 65%. Minoxidil regrows hair in 40–60% of men when used consistently. Together, the response rate approaches 94% — because they work through entirely different mechanisms that complement each other rather than overlap.
Understanding why these medications work together requires understanding why they differ:
Male pattern hair loss (androgenetic alopecia) is driven by DHT (dihydrotestosterone) miniaturizing hair follicles over time. Finasteride inhibits 5-alpha reductase type 2, the enzyme that converts testosterone to DHT, reducing scalp DHT by approximately 70%. By eliminating the primary driver of follicle miniaturization, finasteride stops the progression of hair loss. It does not stimulate hair growth — it removes the signal that is killing follicles.
Minoxidil works through a completely separate pathway — it is a potassium channel opener and vasodilator that increases blood flow to follicles and directly stimulates follicle activity through prostaglandin-related pathways. Minoxidil converts follicles from the telogen (resting/shedding) phase back to the anagen (active growth) phase and prolongs the anagen phase duration. It does not address DHT — it compensates for follicle damage by stimulating the follicle regardless of DHT exposure.
The combination logic: finasteride stops the damage, minoxidil stimulates growth. Neither alone does both.
A 2015 study published in the Journal of the American Academy of Dermatology (Hu et al.) — one of the most cited combination therapy studies — followed men with androgenetic alopecia for 12 months on four arms: finasteride alone, minoxidil alone, combination, and placebo.
The combination group also had significantly greater increases in hair density, shaft diameter, and patient-reported satisfaction than either monotherapy group.
This is an increasingly important clinical question as oral minoxidil has gained traction:
Oral minoxidil at low doses has become increasingly used off-label for androgenetic alopecia. Key advantages:
Key considerations:
YourMD prescribes oral minoxidil off-label for appropriate patients who prefer systemic dosing or have not responded adequately to topical formulations.
Patients fail combination therapy most often because they stop too early. Here is what to actually expect:
The most discussed concern is post-finasteride syndrome (PFS) — reported sexual side effects (decreased libido, erectile dysfunction, ejaculatory dysfunction) that persist after discontinuation in a subset of patients. The clinical trial data from FDA approval shows sexual side effects in approximately 3.8% of patients vs 2.1% placebo — these typically resolve within weeks of stopping finasteride. Persistent post-discontinuation effects remain a subject of medical debate; the mechanism is not established. Patients who are concerned should discuss this with their physician before starting.
The elevated-PSA interaction is important for men over 50: finasteride reduces PSA levels by approximately 50%. A PSA of 2.0 on finasteride may represent what would be 4.0 off the medication. Inform your urologist or primary care physician that you are on finasteride before any PSA-based prostate cancer screening.
For patients with androgenetic alopecia (Norwood II–VI), our standard approach:
Women with female pattern hair loss are eligible for minoxidil (topical or oral) and spironolactone; finasteride is used in select post-menopausal women with physician discussion.
This article is for informational purposes only and does not constitute medical advice. Always consult with a licensed physician before starting any medication.
No credit card required. Live MD consult included.